Diabetic Macular Edema Market By Type 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Diabetic Macular Edema Market
Diabetic Macular Edema Market: By Type (Spongiform, Serous Retinal Detachment); By Treatment Categories (Laser Treatment, Eylea Injection, Intravitreal Steroids); By Geography (Americas, Europe, Asia-Pacific) – With Forecast (2016-2021)
Report Code : HCR 0244
Updated Date: 25 February, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
1. Diabetic Macular Edema  – Market Overview
2. Executive Summary
3. Diabetic Macular Edema  – Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Diabetic Macular Edema – Market Forces
   4.1. Market Drivers
   4.2. Market Constraints
   4.3. Market Challenges
   4.4. Attractiveness of the Diabetic Macular Edema Industry
      4.4.1. Power of Suppliers
      4.4.2. Power of Customers
      4.4.3. Threat of New Entrants
      4.4.4. Threat of Substitution
      4.4.5. Degree of Competition
5.  Diabetic Macular Edema Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Diabetic Macular Edema Market – By Type
   6.1. Spongiform
   6.2. Diffuse Macular Edema
   6.3. Cystoid Macular Edema
   6.4. Serous Retinal Detachment
   6.5. Tractional
   6.6. Taut posterior hyaloid membrane (TPHM)
7. Diabetic Macular Edema Market – By Treatment Methods
   7.1. Laser Treatment
      7.1.1. Focal Laser
      7.1.2. Scatter Laser
      7.1.3. Grid pattern photocoagulation
   7.2. Anti-angiogenic Drugs Injection
      7.2.1. Avastin
      7.2.2. Lucentis
      7.2.3. Eylea
   7.3. Intravitreal Steriods
      7.3.1. Kenalog
      7.3.2. Ozurdex
      7.3.3. lluvien
   7.4. Anti–vascular Endothelial Growth Factor (VEGF) Therapy
   7.5. Others
8. Diabetic Macular Edema Market- By Geography
   8.1. Introduction
   8.2. Global Study
   8.3. Americas
      8.3.1. USA
      8.3.2. Canada
      8.3.3.  Mexico
      8.3.4. Brazil
      8.3.5. Others
   8.4. Europe
      8.4.1. U.K.
      8.4.2. France
      8.4.3. Germany
      8.4.4. Others
   8.5. APAC
      8.5.1. Japan
      8.5.2. China
      8.5.3. South Korea
      8.5.4. Australia
      8.5.5. Others
   8.6. ROW
9. Market Entropy
   9.1. New Product Launches
   9.2. M&As, Collaborations, JVs and Partnerships
10. Company Profiles
   10.1. Allergan PLC
   10.2. Clearside Biomedical, Inc.
   10.3. Novartis AG
   10.4. Valeant Pharmaceuticals (Bausch & Lomb)
   10.5. Regenron PLC
   10.6. pSivida Corporation
   10.7. Pfizer, Inc.
   10.8. Bayer AG
   10.9. Alimera Sciences, Inc.
   10.10. Ariam Pharmaceuticals
*More than 10 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Diabetic Macular Edema (DME) is defined as an accumulation of fluid in the macula of the retina that controls the vision abilities of the human eye. DME is the disease that is followed by diabetic retinopathy. Diabetic retinopathy is a disease that severely damages the blood vessels of the retina, resulting in vision defects or vision loss. These blood vessels if left untreated begin to exert pressure in the eye and result in fluid leakage, causing DME.

The report “Global Diabetic Macular Edema Market” for the projected period 2016 to 2021 has been segmented on three different parameters. The global DME market has been primarily studied on the basis of different categories of Diabetic Macular Edema as per the Optical Coherence Tomography (OCT ) classification that are Spongiform DME, Cystoid Macular Edema and so on. The Diabetic Macular Edema market has also been studied on the basis of different treatment methods such as Anti-angiogenic drugs injection, Laser treatment and many more. The market has also been studied on the basis of different geographies and the level of population affected by the Diabetic Macular Edema disease in those geographies.

Diabetic Macular Edema Market

As per the study conducted by International Diabetes Federation (IDF), approximately 284 million people, almost equivalent to half of the European population are suffering from visually impairments out of which 39 million of them are totally blind. These kinds of diseases in addition to the human aspects also carry significant social as well as economic impact. Medical organizations and pharmaceuticals companies are investing substantially into R&D, infrastructure and technology to tackle the burden of these chronic diseases. DME only affects a certain percentage of diabetic patients; its percentage is likely to grow in the coming years. The number of people suffering from diabetes in Europe is speculated to rise from 55.2 million in 2010 to 66.2 million by 2030, DME cases would increase proportionately. There are several anti VEGF compounds which are being manufactured and currently into research phase. Asia-Pacific region is expected to be one of the emerging markets for DME treatment, as the diabetic population in the developing nations such as India, China and Indonesia are pacing up exponentially.

Sample Companies Profiled in this Report are:

  • Allergan PLC
  • Clearside Biomedical, Inc.
  • Novartis AG
  • Valeant Pharmaceuticals (Bausch & Lomb)
  • Regenron PLC
  • 10+

T0he Diabetic Macular Edema market report also comprises of the leading companies profiled in an extremely descriptive manner. The company profiles include financial summaries, strategies, recent developments and product portfolios of the leading companies in the Diabetic Macular Edema market. The report also incorporates a profound study of the market entropy, market forces and strategic analysis of the Diabetic Macular Edema market.
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports